This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Glatiramer acetate (GA), a synthetic copolymer, is a frequently used first-line treatment for relapsing-remitting multiple sclerosis (RRMS). Probable autoimmune hepatotoxicity during GA treatment has been reported,1–4 but GA hepatotoxicity in the absence of positive autoimmune markers has not previously been described. Here, we report GA-induced hepatotoxicity in a pediatric patient with multiple sclerosis (MS).
Acknowledgments
Acknowledgement: The authors thank Lynn MacMillan for assistance in acquiring patient data for this report.
Footnotes
Supplemental data at www.neurology.org
Author contributions: Dr. Makhani: data acquisition, data analysis, drafting of the manuscript, and review of manuscript for important intellectual content. Dr. Ngan: data acquisition, data analysis, drafting of the manuscript, and review of the manuscript for important intellectual content. Dr. Kamath: data acquisition, data analysis, and review of the manuscript for important intellectual content. Dr. Yeh: data acquisition, data analysis, review of the manuscript for important intellectual content, and study supervision.
Study funding: No targeted funding reported.
Disclosure: N. Makhani received fellowship funding from the Canadian Network of MS Clinics and has received research support from the Dairy Farmers of Ontario. She has received speaker's honoraria from EMD Serono and Teva Neuroscience. B. Ngan reports no disclosures. B. Kamath has received research support from the SickKids Transplant and Regenerative Medicine Center, Alagille Syndrome Alliance, the SickKids Research Institute, NIH, Ashley's Angels Foundation, Rare Disease Foundation, and the American Liver Foundation. E. Yeh has received research support from the National MS Society, MS Society of Canada, CIHR, NIH, the Dairy Farmers of Ontario, Jog for the Jake Foundation, and the Children's Guild Foundation. Go to Neurology.org for full disclosures.
- Received February 20, 2013.
- Accepted in final form May 7, 2013.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
- Glatiramer Acetate - induced Hepatotoxicity in a Patient Naive to Interferon Beta
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
